Literature DB >> 17701469

Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation.

Elizabeth B Haagsma1, Ingrid I Van Gameren, Johan Bijzet, Marcel D Posthumus, Bouke P C Hazenberg.   

Abstract

To estimate the evolution of amyloid in tissue, we studied abdominal fat aspirates of cases with familial amyloidotic polyneuropathy (FAP) longitudinally at regular intervals between 1994 and 2006. In 22 cases (13 carriers and nine patients) not yet transplanted median follow-up was 3.3 years (range 0.4-11.3). We found a significant increase in the amyloid grade of fat tissue from 2+ to 4+ and from 0 to 4+ in two of three subjects with follow-ups of >7 years, after 7 and 11 years, respectively. All other subjects remained negative or did not show a significant change. In 11 liver transplant patients, follow-up with fat aspirate was available with a median duration of 3.1 years (range 1.0-10.1). A comparison was made with cardiac amyloid as judged by the cardiac septum diameter and the serum NT-ProBNP (N-terminal pro-B-type natriuretic peptide) level. No stable increase of amyloid in fat was seen in any patient. A stable decrease of amyloid grade was seen in one patient 5 years after transplantation. In contrast, the cardiac septum diameter increased >or=4 mm in six of the 11 transplant patients. Our study shows the diagnostic utility of a regularly repeated fat aspirate in carriers at risk for the development of ATTR amyloidosis. Evolution of amyloid deposition in fat tissue is very gradual. After liver transplantation, amyloid deposition in fat tissue seems to stabilize and may even decrease in the long term, whereas amyloid deposition in cardiac tissue appears to be progressive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701469     DOI: 10.1080/13506120701461368

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  6 in total

Review 1.  Nuclear imaging for cardiac amyloidosis.

Authors:  Walter Noordzij; Andor W J M Glaudemans; Simone Longhi; Riemer H J A Slart; Massimiliano Lorenzini; Bouke P C Hazenberg; Claudio Rapezzi
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

2.  Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain.

Authors:  Ingrid I van Gameren; Martin H van Rijswijk; Johan Bijzet; Edo Vellenga; Bouke P Hazenberg
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

3.  Biopsy of subcutaneus fatty tissue for diagnosis of systemic amyloidosis.

Authors:  B Bogov; M Lubomirova; B Kiperova
Journal:  Hippokratia       Date:  2008       Impact factor: 0.471

4.  Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis.

Authors:  Elisabet Ihse; Ole B Suhr; Ulf Hellman; Per Westermark
Journal:  J Mol Med (Berl)       Date:  2010-11-25       Impact factor: 4.599

5.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Authors:  Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2012-05-15       Impact factor: 5.460

6.  Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges.

Authors:  Marianna Bruno; Adam Castaño; Arianna Burton; Justin L Grodin
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.